Regulation of cancer cell migration and bone metastasis by RANKL.
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Bone metastases are a frequent complication of many cancers that result in severe disease burden and pain. Since the late nineteenth century, it has been thought that the microenvironment of the local host tissue actively participates in the propensity of certain cancers to metastasize to specific organs, and that bone provides an especially fertile 'soil'. In the case of breast cancers, the local chemokine milieu is now emerging as an explanation for why these tumours preferentially metastasize to certain organs. However, as the inhibition of chemokine receptors in vivo only partially blocks metastatic behaviour, other factors must exist that regulate the preferential metastasis of breast cancer cells. Here we show that the cytokine RANKL (receptor activator of NF-kappaB ligand) triggers migration of human epithelial cancer cells and melanoma cells that express the receptor RANK. RANK is expressed on cancer cell lines and breast cancer cells in patients. In a mouse model of melanoma metastasis, in vivo neutralization of RANKL by osteoprotegerin results in complete protection from paralysis and a marked reduction in tumour burden in bones but not in other organs. Our data show that local differentiation factors such as RANKL have an important role in cell migration and the tissue-specific metastatic behaviour of cancer cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MDA-231 cells and other human breast cancer cells have been shown to express RANK (101, 336)”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [336]
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationInvolvement of chemokine receptors in breast cancer metastasis
Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., et al. (2001) · Nature · doi:10.1038/35065016 · Cited by 5,340
The distribution of secondary growths in cancer of the breast.
Paget, S. (1889) · The Lancet · doi:10.1016/s0140-6736(00)49915-0 · Cited by 5,277
Bone Resorption by Osteoclasts
Teitelbaum, S. L. (2000) · Science · doi:10.1126/science.289.5484.1504 · Cited by 3,962
Dissemination and growth of cancer cells in metastatic sites
Chambers, A. F., Groom, A. C., & MacDonald, I. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc865 · Cited by 3,911
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351
Self-citationMetastasis to bone: causes, consequences and therapeutic opportunities
Mundy, G. R. (2002) · Nature Reviews Cancer · doi:10.1038/nrc867 · Cited by 2,777
The microenvironment of the tumour–host interface
Liotta, L. A., & Kohn, E. C. (2001) · Nature · doi:10.1038/35077241 · Cited by 2,310
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Fata, J. E., Kong, Y.-Y., Li, J., Sasaki, T., Irie-Sasaki, J., Moorehead, R. A., Elliott, R., Scully, S., Voura, E. B., Lacey, D. L., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)00103-3 · Cited by 756
Self-citation
Cited by
Cancer Metastasis: Building a Framework
Gupta, G. P., & Massagué, J. (2006) · Cell · doi:10.1016/j.cell.2006.11.001 · Cited by 4,247
“A recent study suggests that this receptor-ligand combination may predispose breast-cancer cells to bone colonization (Jones et al., 2006).”
BackgroundMicroenvironmental regulation of metastasis
Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684
The extracellular matrix: A dynamic niche in cancer progression
Lu, P., Weaver, V. M., & Werb, Z. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201102147 · Cited by 3,024
Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems
Takayanagi, H. (2007) · Nature Reviews Immunology · doi:10.1038/nri2062 · Cited by 1,878
Functions of RANKL/RANK/OPG in bone modeling and remodeling
Boyce, B. F., & Xing, L. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.03.018 · Cited by 1,844
The metastatic niche: adapting the foreign soil
Psaila, B., & Lyden, D. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2621 · Cited by 1,300
Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth
Zhang, L., Zhang, S., Yao, J., Lowery, F. J., Zhang, Q., Huang, W.-C., Li, P., Li, M., Wang, X., Zhang, C., et al. (2015) · Nature · doi:10.1038/nature15376 · Cited by 1,175
Hiratsuka, S., Watanabe, A., Aburatani, H., & Maru, Y. (2006) · Nature Cell Biology · doi:10.1038/ncb1507 · Cited by 1,015
Sheridan, C., Kishimoto, H., Fuchs, R. K., Mehrotra, S., Bhat-Nakshatri, P., Turner, C. H., Goulet, R., Badve, S., & Nakshatri, H. (2006) · Breast Cancer Research · doi:10.1186/bcr1610 · Cited by 993
“A recent study described the role of the receptor activator of nuclear factor-κB (RANK)/ RANK ligand in metastasis of breast cancer cells to bone [16].”
BackgroundKearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Smith, M. R., Saad, F., Coleman, R., Shore, N., Fizazi, K., Tombal, B., Miller, K., Sieber, P., Karsh, L., Damião, R., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61226-9 · Cited by 797
Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells
Kollet, O., Dar, A., Shivtiel, S., Kalinkovich, A., Lapid, K., Sztainberg, Y., Tesio, M., Samstein, R. M., Goichberg, P., Spiegel, A., et al. (2006) · Nature Medicine · doi:10.1038/nm1417 · Cited by 775
Macedo, F., Ladeira, K., Pinho, F., Saraiva, N., Bonito, N., Pinto, L., & Gonçalves, F. (2017) · Oncology Reviews · doi:10.4081/oncol.2017.321 · Cited by 775
Osteoimmunology: evolving concepts in bone–immune interactions in health and disease
Tsukasaki, M., & Takayanagi, H. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0178-8 · Cited by 771
Genetics and biology of prostate cancer
Wang, G., Zhao, D., Spring, D. J., & DePinho, R. A. (2018) · Genes & Development · doi:10.1101/gad.315739.118 · Cited by 750
“Activated RANK–RANKL signaling in prostate cancer cells is also implicated in the colonization of cancer cells in the bone (Jones et al. 2006).”
BackgroundMechanistic Pathways of Sex Differences in Cardiovascular Disease
Regitz-Zagrosek, V., & Kararigas, G. (2017) · Physiological Reviews · doi:10.1152/physrev.00021.2015 · Cited by 732
“The receptor activator of NF- B ligand (RANKL), its receptor RANK, and the decoy receptor osteoprotegerin also appear to be involved in the inflammatory process (146, 176, 350).”
BackgroundBench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab
Lacey, D. L., Boyle, W. J., Simonet, W. S., Kostenuik, P. J., Dougall, W. C., Sullivan, J. K., Martin, J. S., & Dansey, R. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3705 · Cited by 694
Tan, W., Zhang, W., Strasner, A., Grivennikov, S., Cheng, J. Q., Hoffman, R. M., & Karin, M. (2011) · Nature · doi:10.1038/nature09707 · Cited by 647
Chen, Q., Zhang, X. H.-F., & Massagué, J. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.025 · Cited by 619
“…genes directly participate in the ultimate colonization of the invaded organs, an event that may take place after a latency period lasting months or decades depending on the type of cancer (Jones et al., 2006; Kang et al., 2003; Mu¨ller et al., 2001; Pa`ez-Ribes et al., 2009; Yin et al., 1999).”
BackgroundBiology of the RANKL–RANK–OPG System in Immunity, Bone, and Beyond
Walsh, M. C., & Choi, Y. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00511 · Cited by 599
“With respect to showing the contribution of local differentiation factors, in addition to chemotactic factors, to metastasis, it was shown that RANKL stimulation directly triggered metastasis of melanoma cell lines and breast cancer in patients in a manner that is independent of pro-osteoclastic activity (122).”
BackgroundOsteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer
Schramek, D., Leibbrandt, A., Sigl, V., Kenner, L., Pospisilik, J. A., Lee, H. J., Hanada, R., Joshi, P. A., Aliprantis, A., Glimcher, L., et al. (2010) · Nature · doi:10.1038/nature09387 · Cited by 592
Self-citationRANKL biology: bone metabolism, the immune system, and beyond
Ono, T., Hayashi, M., Sasaki, F., & Nakashima, T. (2020) · Inflammation and Regeneration · doi:10.1186/s41232-019-0111-3 · Cited by 578
Self-citationSurviving at a Distance: Organ-Specific Metastasis
Obenauf, A. C., & Massagué, J. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.07.009 · Cited by 565
“, CXCL12, RANKL, OPN, or BMPs) that recruit cancer cells to the bone marrow [41,42] (Figure 2, top).”
A Microenvironment-Induced Myeloproliferative Syndrome Caused by Retinoic Acid Receptor γ Deficiency
Walkley, C. R., Olsen, G. H., Dworkin, S., Fabb, S. A., Swann, J., McArthur, G. A., Westmoreland, S. V., Chambon, P., Scadden, D. T., & Purton, L. E. (2007) · Cell · doi:10.1016/j.cell.2007.05.014 · Cited by 536
“Several previous reports have suggested that adipocytes and adipose tissue are capable of supporting hematopoiesis, including myelopoiesis (Corre et al., 2004; Cousin et al., 2003; Hangoc et al., 1993 ).”
Osteoimmunology: The conceptual framework unifying the immune and skeletal systems
Okamoto, K., Nakashima, T., Shinohara, M., Negishi-Koga, T., Komatsu, N., Terashima, A., Sawa, S., Nitta, T., & Takayanagi, H. (2017) · Physiological Reviews · doi:10.1152/physrev.00036.2016 · Cited by 534
“RANKL serves as a chemotactic and survival factor for osteoclast lineage cells (193, 195), but it has remained unclear how membrane-bound and soluble forms specifically contribute to such functions.”
BackgroundSelf-citationBone metastasis: the importance of the neighbourhood
Croucher, P. I., McDonald, M. M., & Martin, T. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.44 · Cited by 479
Nuclear cytokine-activated IKKα controls prostate cancer metastasis by repressing Maspin
Luo, J.-L., Tan, W., Ricono, J. M., Korchynskyi, O., Zhang, M., Gonias, S. L., Cheresh, D. A., & Karin, M. (2007) · Nature · doi:10.1038/nature05656 · Cited by 436
Bone metastasis: mechanisms, therapies, and biomarkers
Clézardin, P., Coleman, R., Puppo, M., Ottewell, P., Bonnelye, E., Paycha, F., Confavreux, C. B., & Holen, I. (2021) · Physiological Reviews · doi:10.1152/physrev.00012.2019 · Cited by 416
Lipton, A., Steger, G. G., Figueroa, J., Alvarado, C., Solal-Celigny, P., Body, J.-J., de Boer, R., Berardi, R., Gascon, P., Tonkin, K. S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8604 · Cited by 389
Immune cells as mediators of solid tumor metastasis
DeNardo, D. G., Johansson, M., & Coussens, L. M. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9100-0 · Cited by 372
“Though RANKL has not been shown to directly repress maspin in breast cancers, RANKL-mediated RANK activation induces migratory behavior in both breast and prostate carcinomas [69] and maspin over-expression from a mammary epithelial promoter inhibited metastasis of SV40 Tag-induced mammary carcinomas [70].”
BackgroundLGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption
Luo, J., Yang, Z., Ma, Y., Yue, Z., Lin, H., Qu, G., Huang, J., Dai, W., Li, C., Zheng, C., et al. (2016) · Nature Medicine · doi:10.1038/nm.4076 · Cited by 370
Self-citationTse, J. C., & Kalluri, R. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21215 · Cited by 370
Bone marrow cells in the ‘pre-metastatic niche’: within bone and beyond
Kaplan, R. N., Psaila, B., & Lyden, D. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9036-9 · Cited by 336
“Here, blocking RANKL with its decoy receptor osteoprotegerin reduced tumor burden in bone exclusively, with no change in metastatic deposition in ovaries, adrenal glands, and brain [72].”
BackgroundScagliotti, G. V., Hirsh, V., Siena, S., Henry, D. H., Woll, P. J., Manegold, C., Solal-Celigny, P., Rodriguez, G., Krzakowski, M., Mehta, N. D., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31826aec2b · Cited by 335
“RANKL inhibition may have a direct antineoplastic effect on lung cancer cells via apoptosis or antimigration activity.(26) In our study, denosumab was also associated with improved overall survival in lung cancer patients with visceral metastases, which commonly determine the pace of disease progression and death.”
BackgroundMetastasis: a therapeutic target for cancer
Steeg, P. S., & Theodorescu, D. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1066 · Cited by 332
Mouse models of breast cancer metastasis
Fantozzi, A., & Christofori, G. (2006) · Breast Cancer Research · doi:10.1186/bcr1530 · Cited by 331
Park, B. K., Zhang, H., Zeng, Q., Dai, J., Keller, E. T., Giordano, T., Gu, K., Shah, V., Pei, L., Zarbo, R. J., et al. (2007) · Nature Medicine · doi:10.1038/nm1519 · Cited by 325
Liu, Y.-C. G., Lerner, U. H., & Teng, Y.-T. A. (2010) · Periodontology 2000 · doi:10.1111/j.1600-0757.2009.00321.x · Cited by 306
Organotropism of Breast Cancer Metastasis
Lu, X., & Kang, Y. (2007) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-007-9047-3 · Cited by 259
“RANK was also found to be expressed in breast cancer cells and promote invasion, migration and tissuespecific metastasis to bone in response to stimulation by RANKL, which is abundant in bone [31].”
Macedo, F. (2017) · Cancer therapy & Oncology International Journal · doi:10.19080/ctoij.2017.04.555637 · Cited by 257
Impact of the Autonomic Nervous System on the Skeleton
Elefteriou, F. (2018) · Physiological Reviews · doi:10.1152/physrev.00014.2017 · Cited by 241
“Among these cytokines, RANKL has been implicated as a critical osteotropic factor, released by bone cells, for metastatic cancer cells from breast and prostate carcinomas (68, 139, 300).”
BackgroundSmith, M. R., Saad, F., Oudard, S., Shore, N., Fizazi, K., Sieber, P., Tombal, B., Damiao, R., Marx, G., Miller, K., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.6716 · Cited by 241
“Furthermore, because some prostate cancers express RANK,(16) RANKL produced by osteoblasts and bone marrow stromal cells may contribute to homing of RANK-positive prostate cancer cells to bone.(17) Denosumab is a fully human monoclonal antibody that specifically binds and blocks RANKL activation and is currently appro…”
BackgroundDiscovery of the RANKL/RANK/OPG system
Yasuda, H. (2021) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-020-01175-1 · Cited by 234
“OPG-Fc or RANK-Fc inhibits metastasis and proliferation by binding to RANK-positive cancer cells [43, 46, 47].”
BackgroundNF-κB modulators in osteolytic bone diseases
Xu, J., Wu, H. F., Ang, E. S. M., Yip, K., Woloszyn, M., Zheng, M. H., & Tan, R. X. (2009) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2008.11.007 · Cited by 229
The dual role of IL-6-type cytokines on bone remodeling and bone tumors
Blanchard, F., Duplomb, L., Baud’huin, M., & Brounais, B. (2009) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2008.11.004 · Cited by 218
“4) [5,39–42].”
BackgroundOsteoimmunology: Crosstalk Between the Immune and Bone Systems
Nakashima, T., & Takayanagi, H. (2009) · Journal of Clinical Immunology · doi:10.1007/s10875-009-9316-6 · Cited by 216
“In addition, previous studies have indicated that RANKL serves as both a chemotactic and survival factor for osteoclasts [33, 34].”
BackgroundSelf-citationTumor αvβ3 Integrin Is a Therapeutic Target for Breast Cancer Bone Metastases
Zhao, Y., Bachelier, R., Treilleux, I., Pujuguet, P., Peyruchaud, O., Baron, R., Clément-Lacroix, P., & Clézardin, P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4499 · Cited by 210
“Bone-derived cytokine receptor activator of nuclear factor-nB ligand (RANKL) has been involved recently in the bone tropism of RANK-expressing cancer cells ( 24 ).”
BackgroundCanon, J. R., Roudier, M., Bryant, R., Morony, S., Stolina, M., Kostenuik, P. J., & Dougall, W. C. (2008) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9127-1 · Cited by 209
“For instance, RANKL has been demonstrated to act as a chemotactic factor [30] and these recent studies suggested that RANKL may recruit RANKexpressing tumor cells to migrate into the bone environment.”
BackgroundSelf-citationNovel approaches to target the microenvironment of bone metastasis
Hofbauer, L. C., Bozec, A., Rauner, M., Jakob, F., Perner, S., & Pantel, K. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00499-9 · Cited by 207
A Cathepsin K Inhibitor Reduces Breast Cancer–Induced Osteolysis and Skeletal Tumor Burden
Le Gall, C., Bellahcène, A., Bonnelye, E., Gasser, J. A., Castronovo, V., Green, J., Zimmermann, J., & Clézardin, P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3940 · Cited by 204
Palafox, M., Ferrer, I., Pellegrini, P., Vila, S., Hernandez-Ortega, S., Urruticoechea, A., Climent, F., Soler, M. T., Muñoz, P., Viñals, F., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0044 · Cited by 199
“It has been shown that RANK signaling induces migration and bone metastasis in human breast cancer lines (41).”
BackgroundCampbell, J. P., Karolak, M. R., Ma, Y., Perrien, D. S., Masood-Campbell, S. K., Penner, N. L., Munoz, S. A., Zijlstra, A., Yang, X., Sterling, J. A., et al. (2012) · PLoS Biology · doi:10.1371/journal.pbio.1001363 · Cited by 199
“pharmacological blockade of the SDF1-CXCR4 axis by AMD3100, a CXCR4 antagonist, does not fully prevent bone metastasis [27].”
BackgroundInfluentialDougall, W. C. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2507 · Cited by 198
The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease
Kiechl, S., Werner, P., Knoflach, M., Furtner, M., Willeit, J., & Schett, G. (2006) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.4.6.801 · Cited by 195
Molecular mechanisms and clinical management of cancer bone metastasis
Wang, M., Xia, F., Wei, Y., & Wei, X. (2020) · Bone Research · doi:10.1038/s41413-020-00105-1 · Cited by 193
“Although RANK is considered to be primarily expressed on osteoclasts and their progenitors, recent studies have also detected its expression on tumor cells, indicating the potential participation of RANK in tumor metastasis.(76,77) RANKL is a polypeptide that belongs to type II transmembrane proteins.”
BackgroundPratap, J., Wixted, J. J., Gaur, T., Zaidi, S. K., Dobson, J., Gokul, K. D., Hussain, S., van Wijnen, A. J., Stein, J. L., Stein, G. S., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1078 · Cited by 191
“Downstream events of IHH signaling in breast cancer cells result in activation of PTHrP and consequently activates osteoclasts through RANKL.”
InfluentialThe RANK–RANKL–OPG System: A Multifaceted Regulator of Homeostasis, Immunity, and Cancer
León-Oliva, D. D., Barrena-Blázquez, S., Jiménez-Álvarez, L., Fraile‐Μartinez, O., Montero, C. G., López-González, L., Torres‐Carranza, D., García-Puente, L. M., Carranza, S. T., Álvarez-Mon, M. Á., et al. (2023) · Medicina · doi:10.3390/medicina59101752 · Cited by 192
“The expression of RANK by some metastatic cancer cells of epithelial tumors leads to the attachment of RANKL in the bones [81].”
BackgroundPathogenesis of osteoblastic bone metastases from prostate cancer
Ibrahim, T., Flamini, E., Mercatali, L., Sacanna, E., Serra, P., & Amadori, D. (2010) · Cancer · doi:10.1002/cncr.24896 · Cited by 190
“In preclinical and clinical trials, inhibition of RANKL with OPG reduces bone turnover markers,(119) suggesting that RANKL, in addition to having an effect on bone lysis, also has a direct action on tumor cells.(120,121) The anti-RANKL monoclo-”
The RANK/RANKL/OPG triad in cancer-induced bone diseases
Dougall, W. C., & Chaisson, M. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9021-3 · Cited by 187
“Breast, primary and metastatic tumors, cell lines IHC, RT–PCR [53] [80] [75] [ 76 ]”
BackgroundInfluentialSantini, D., Schiavon, G., Vincenzi, B., Gaeta, L., Pantano, F., Russo, A., Ortega, C., Porta, C., Galluzzo, S., Armento, G., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019234 · Cited by 185
“by 50% and prevented tumor-induced paralysis [29].”
BackgroundAdvances in the biology of bone metastasis: How the skeleton affects tumor behavior
Sterling, J. A., Edwards, J. R., Martin, T. J., & Mundy, G. R. (2011) · Bone · doi:10.1016/j.bone.2010.07.015 · Cited by 184
“[94] to show that RANKL promoted motility of cancer cells expressing”
BackgroundControl of canonical NF-κB activation through the NIK–IKK complex pathway
Zarnegar, B., Yamazaki, S., He, J. Q., & Cheng, G. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707959105 · Cited by 183
The role of Src in prostate cancer
Fizazi, K. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm086 · Cited by 183
Lamoureux, F., Richard, P., Wittrant, Y., Battaglia, S., Pilet, P., Trichet, V., Blanchard, F., Gouin, F., Pitard, B., Heymann, D., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4130 · Cited by 181
“(13) shows that in vivo neutralization of RANKL by OPG results in complete protection from paralysis and a marked reduction in tumor burden in bones in a mouse model of melanoma metastasis, but not in other organs.”
BackgroundMethodInfluentialRANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives
Infante, M., Fabi, A., Cognetti, F., Gorini, S., Caprio, M., & Fabbri, A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-1001-2 · Cited by 180
“Therapeutic perspectives in humans: targeting RANKL/RANK/OPG system for prevention and treatment of breast cancer As previously discussed, RANKL accelerates the migration and metastasis of RANK-expressing cancer cells [24] and acts as the final effector of osteoclastogenesis in the vicious cycle of bone destruction in…”
BackgroundArmstrong, A. P., Miller, R. E., Jones, J. C., Zhang, J., Keller, E. T., & Dougall, W. C. (2008) · The Prostate · doi:10.1002/pros.20678 · Cited by 180
“The functional role of RANK on mammary epithelial cells [25] and tumors of epithelial origin [19,26,20] suggests”
InfluentialMolecular Mechanisms and Emerging Therapeutic Targets of Triple-Negative Breast Cancer Metastasis
Neophytou, C., Boutsikos, P., & Papageorgis, P. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00031 · Cited by 173
Navigating the bone marrow niche: translational insights and cancer-driven dysfunction
Reagan, M. R., & Rosen, C. J. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.160 · Cited by 173
Rauner, M., Sipos, W., & Pietschmann, P. (2007) · International Archives of Allergy and Immunology · doi:10.1159/000098223 · Cited by 132
Nagy, V., & Penninger, J. M. (2015) · Gerontology · doi:10.1159/000371845 · Cited by 171
Self-citationRANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases
Baud’huin, M., Lamoureux, F., Duplomb, L., Rédini, F., & Heymann, D. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7104-0 · Cited by 170
The Biology of Bone Metastasis
Esposito, M., Guise, T., & Kang, Y. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031252 · Cited by 170
“This expression was instructive in guiding migration along RANKL gradients in vitro, and growth of non-osteolytic bone metastases were slowed by OPG treatment in vivo (Jones et al. 2006).”
Understanding hematopoietic stem-cell microenvironments
Li, Z., & Li, L. (2006) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.08.001 · Cited by 170
Bone Metastasis of Breast Cancer
Tahara, R. K., Brewer, T. M., Theriault, R. L., & Ueno, N. T. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-20301-6_7 · Cited by 169
Cancer-associated bone disease
Rizzoli, R., Body, J. J., Brandi, M. L., Cannata-Andía, J. B., Chappard, D., Maghraoui, A. E., Glüer, C.-C., Kendler, D., Napoli, N., Παπαϊωάννου, Α., et al. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2530-3 · Cited by 163
“In a mouse model, by blocking RANKL, OPG resulted in a reduction in tumour burden in bone, but not in other organs [28].”
BackgroundLipton, A., Steger, G. G., Figueroa, J., Alvarado, C., Solal-Celigny, P., Body, J. J., de Boer, R., Berardi, R., Gascon, P., Tonkin, K. S., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5234 · Cited by 162
NF-κB as a central regulator of macrophage function in tumors
Biswas, S. K., & Lewis, C. E. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0310153 · Cited by 161
“noma [70–72].”
RANK–RANKL signalling in cancer
Renema, N., Navet, B., Heymann, M.-F., Lezot, F., & Heymann, D. (2016) · Bioscience Reports · doi:10.1042/bsr20160150 · Cited by 161
Bone metastasis: pathogenesis and therapeutic implications
Clézardin, P., & Teti, A. M. (2007) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9112-8 · Cited by 159
“RANKL interaction, blocks the bone tropism of these cancer cells in vivo [30].”
BackgroundManaging bone metastases and reducing skeletal related events in prostate cancer
Gartrell, B. A., & Saad, F. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.70 · Cited by 158
Kollet, Ó., Dar, A., & Lapidot, T. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141631 · Cited by 157
New understanding and treatments for osteoporosis
Mazziotti, G., Bilezikian, J. P., CANALIS, E. M., Cocchi, D., & Giustina, A. (2011) · Endocrine · doi:10.1007/s12020-011-9570-2 · Cited by 156
Calcium sensing receptor signalling in physiology and cancer
Brennan, S. C., Thiem, U., Roth, S., Aggarwal, A., Fetahu, I. S., Tennakoon, S., Gomes, A. R., Brandi, M. L., Bruggeman, F. J., Mentaverri, R., et al. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.12.011 · Cited by 156
Odero‐Marah, V., Wang, R., Chu, G. C., Zayzafoon, M., Xu, J., Shi, C., Marshall, F. F., Zhau, H. E., & Chung, L. W. K. (2008) · Cell Research · doi:10.1038/cr.2008.84 · Cited by 155
Opportunities for improving the therapeutic ratio for patients with sarcoma
Wunder, J. S., Nielsen, T. O., Maki, R. G., O’Sullivan, B., & Alman, B. A. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70169-9 · Cited by 155
Hanada, R., Hanada, T., Sigl, V., Schramek, D., & Penninger, J. M. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0749-z · Cited by 154
“Moreover, OPG-treated mice did not develop any metastasis-induced paralysis [17].”
BackgroundInfluentialSelf-citationMolloy, A. P., Martin, F. T., Dwyer, R. M., Griffin, T. P., Murphy, M., Barry, F. P., O'Brien, T., & Kerin, M. J. (2009) · International Journal of Cancer · doi:10.1002/ijc.23939 · Cited by 128
Fernandez‐Valdivia, R., Mukherjee, A., Yan, Y., Li, J., Paquet, M., DeMayo, F. J., & Lydon, J. P. (2009) · Developmental Biology · doi:10.1016/j.ydbio.2009.01.019 · Cited by 147
Akiyama, T., Dass, C. R., & Choong, P. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0530 · Cited by 146
“tasis of human epithelial cancer cells and melanoma cells that express RANK (73).”
BackgroundKlughammer, J., Abravanel, D. L., Segerstolpe, Å., Blosser, T. R., Goltsev, Y., Cui, Y., Goodwin, D., Sinha, A., Ashenberg, O., Slyper, M., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03215-z · Cited by 145
Hiraoka, K., Zenmyo, M., Watari, K., Iguchi, H., Fotovati, A., Kimura, Y. N., Hosoi, F., Shoda, T., Nagata, K., Osada, H., et al. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00880.x · Cited by 132
Takegahara, N., Kim, H., & Choi, Y. (2022) · Bone · doi:10.1016/j.bone.2022.116353 · Cited by 143
Bone-on-a-chip: Microfluidic technologies and microphysiologic models of bone tissue
Mansoorifar, A., Gordon, R., Bergan, R. C., & Bertassoni, L. E. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202006796 · Cited by 142
RANK ligand as a therapeutic target for bone metastases and multiple myeloma
Roodman, G. D., & Dougall, W. C. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.09.002 · Cited by 142
Targeting tumor–stromal interactions in bone metastasis
Esposito, M., & Kang, Y. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.10.006 · Cited by 129
The anti-tumor effect of RANKL inhibition in malignant solid tumors – A systematic review
de Groot, A. F., Appelman‐Dijkstra, N. M., van der Burg, S. H., & Kroep, J. R. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.10.010 · Cited by 140
Gonzalez-Suarez, E., Branstetter, D., Armstrong, A., Dinh, H., Blumberg, H., & Dougall, W. C. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01298-06 · Cited by 129
“While RANK expression has been detected in breast cancer lines and in primary tumors including breast tumors (45) and may play a functional role in tumor cell migration and metastasis to the bone (24), it is not clear whether activation of the RANK/RANKL pathway may also contribute to primary tumor growth.”
BackgroundThe Role of RANK-Ligand Inhibition in Cancer: The Story of Denosumab
Castellano, D., Sepúlveda-Sánchez, J. M., García-Escobar, I., Rodríguez-Antolín, A., Sundlöv, A., & Cortés-Funes, H. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0154 · Cited by 138
Santini, D., Perrone, G., Roato, I., Godio, L., Pantano, F., Grasso, D., Russo, A. D., Vincenzi, B., Fratto, M. E., Sabbatini, R., et al. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22402 · Cited by 138
Prevention and Management of Bone Metastases in Lung Cancer: A Review
Husaini, H. A., Wheatley‐Price, P., Clemons, M. J., & Shepherd, F. A. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31819518fc · Cited by 136
Metadata
- Authors
- Jones, D. H., Nakashima, T., Sanchez, O. H., Kozieradzki, I., Komarova, S. V., Sarosi, I., Morony, S., Rubin, E., Sarao, R., Hojilla, C. V., Komnenovic, V., Kong, Y.-Y., Schreiber, M., Dixon, S. J., Sims, S. M., Khokha, R., Wada, T., & Penninger, J. M.
- Affiliations
- Institute of Molecular Biotechnology (AT)
- University Health Network (CA)
- McGill University (CA)
- Amgen (United States) (US)
- University of Toronto (CA)
- Pohang University of Science and Technology (KR)
- Medical University of Vienna (AT)
- Western University (CA)
- Corresponding author
- Penninger, Josef M.
- ORCID
- Venue
- Nature
- Published
- 2006-03
- Volume
- 440
- Issue
- 7084
- Pages
- 692-696
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2051255001
- Cited by
- 796
- References
- 22
- Citations by year
- 2026: 10 · 2025: 21 · 2024: 24 · 2023: 32 · 2022: 33 · 2021: 43 · 2020: 43 · 2019: 39 · 2018: 28 · 2017: 43 · 2016: 36 · 2015: 42 · 2014: 45 · 2013: 47 · 2012: 68
- FWCI
- 18.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Scholarship@Western (Western University) (submittedVersion)
- Open Access System for Information Sharing (Pohang University of Science and Technology) (submittedVersion)
- Funders
- European Commission
- Oesterreichische Nationalbank
- Canadian Institutes of Health Research
- National Cancer Institute
- Institute of Musculoskeletal Health and Arthritis
- Canadian Arthritis Network
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- RANKL, RANK, bone metastasis, tumor cell migration, osteoprotegerin, melanoma, breast cancer, tumor microenvironment, NF-κB signaling
- MeSH terms
- Animals, Bone Neoplasms, Breast Neoplasms, Carrier Proteins, Cell Differentiation, Cell Movement, Epithelial Cells, Female, Humans, Melanoma, Membrane Glycoproteins, Neoplasm Metastasis, Organ Specificity, Paralysis, Signal Transduction, Cell Death, Cell Line, Tumor, Cell Proliferation, Mice, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.